Rezdiffra (Resmetirom) and Diphenhydramine Interaction: What Patients and Clinicians Need to Know

What Is the Resmetirom, Diphenhydramine Interaction?

Resmetirom and diphenhydramine do not share a single catastrophic pharmacokinetic clash, but the combination still carries meaningful clinical risk through two overlapping pathways: additive central nervous system (CNS) depression and compounding anticholinergic burden on a liver already stressed by MASH. Both effects are predictable, dose-dependent, and manageable with the right monitoring plan.

The FDA approved resmetirom (Rezdiffra) in March 2024 as the first drug specifically indicated for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis. The prescribing information lists resmetirom as a CYP2C8 substrate and a P-glycoprotein (P-gp) inhibitor at clinically relevant concentrations. Diphenhydramine is primarily metabolized by CYP2D6 and CYP2C9 with N-demethylation steps handled partly by CYP2C19. Diphenhydramine's pharmacology has been characterized since the late 1990s, establishing its broad receptor binding profile that goes well beyond H1 blockade.

Why This Combination Comes Up in Clinical Practice

MASH patients are typically middle-aged to older adults carrying obesity, type 2 diabetes, and dyslipidemia. Sleep disruption is nearly universal in this population, and diphenhydramine is among the most purchased OTC sleep aids in the United States. A 2023 CDC analysis found that 8.4% of adults reported using sleep medication in the past 30 days, with OTC antihistamines representing a substantial share. Because diphenhydramine does not require a prescription, patients rarely mention it proactively during medication reconciliation.

Resmetirom's Metabolic Footprint

Resmetirom is absorbed rapidly after oral dosing and reaches steady state within approximately 14 days. The phase 3 MAESTRO-NASH trial (N=966) demonstrated 26.0% histological resolution of MASH at 80 mg and 29.9% at 100 mg versus 9.7% placebo at 52 weeks (P<0.001). Its thyroid hormone receptor beta (THR-beta) selectivity minimizes cardiac and bone effects, but hepatic metabolism means that any drug altering CYP enzyme activity or hepatic blood flow can shift resmetirom exposure. The FDA label notes that strong CYP2C8 inhibitors (e.g., gemfibrozil) can increase resmetirom AUC substantially; diphenhydramine is not a strong CYP2C8 inhibitor, but the principle underscores how sensitive resmetirom's exposure is to enzymatic context. Full CYP interaction data from the resmetirom NDA package confirm CYP2C8 as the dominant clearance pathway.

Pharmacokinetic Mechanisms: How Each Drug Is Processed

Resmetirom's CYP2C8 Dependence

Resmetirom is cleared predominantly via CYP2C8-mediated oxidation in the liver. The FDA label for Rezdiffra recommends avoiding concomitant strong CYP2C8 inhibitors and advises caution with moderate inhibitors. Diphenhydramine's inhibitory effect on CYP2C8 is negligible in published in vitro panels, meaning that route of elimination does not produce a clinically meaningful pharmacokinetic interaction for resmetirom concentrations specifically.

Resmetirom also inhibits P-gp at intestinal and possibly hepatic levels. In vitro transporter studies show IC50 values for P-gp inhibition by resmetirom that could, at therapeutic plasma concentrations, alter the efflux of co-administered P-gp substrates. Diphenhydramine is not classified as a primary P-gp substrate in standard databases, so this transporter interaction is not expected to be clinically significant for the diphenhydramine side of the equation.

Diphenhydramine's Hepatic Metabolism in a Diseased Liver

This is where MASH patients face a distinct risk that healthy-volunteer PK studies cannot fully capture. Diphenhydramine undergoes extensive first-pass hepatic metabolism. A pharmacokinetic study in patients with hepatic impairment found that diphenhydramine's elimination half-life is prolonged from a normal range of 4 to 9 hours to as long as 15 hours in patients with significant liver disease. MASH with F2, F3 fibrosis represents a continuum of impaired hepatic reserve, and resmetirom's own prescribing information excludes patients with Child-Pugh B or C disease from current approved use. Patients at the border of Child-Pugh A and B may experience disproportionately elevated diphenhydramine exposure when dosed nightly for sleep, accumulating sedative and anticholinergic effects across days.

P-gp Inhibition and Systemic Exposure

The resmetirom label warns that co-administration with sensitive P-gp substrates may increase those substrates' systemic exposure. The FDA's drug interaction guidance lists resmetirom as an inhibitor of P-gp and BCRP at the gut wall. While diphenhydramine is not a principal P-gp substrate, this interaction mechanism matters for clinicians choosing between diphenhydramine and alternative agents that are P-gp substrates (e.g., certain opioids or antidiarrheals), as those combinations carry a higher pharmacokinetic burden.

Pharmacodynamic Mechanisms: The CNS and Anticholinergic Overlap

CNS Sedation

Diphenhydramine crosses the blood-brain barrier readily due to its lipophilicity, producing sedation through H1 receptor antagonism in the CNS. Resmetirom itself is not primarily sedating, but MASH patients are often co-prescribed medications with CNS-depressant properties: opioid analgesics for musculoskeletal pain, benzodiazepines for anxiety, or gabapentinoids for neuropathy related to diabetes. Adding diphenhydramine layers onto an existing sedative stack. A Cochrane systematic review of diphenhydramine for insomnia found that residual morning sedation was reported in 16 to 38% of participants even at standard 25 to 50 mg doses.

Residual sedation in a MASH patient driving to a morning clinic appointment or managing complex insulin regimens is not a trivial concern. The interaction is pharmacodynamic and additive, not synergistic, but additive CNS depression in a population with baseline fatigue from liver disease can cross a functional impairment threshold with small dose changes.

Anticholinergic Burden

Diphenhydramine has one of the highest anticholinergic ratings of any OTC drug. The American Geriatrics Society 2023 Beers Criteria explicitly lists diphenhydramine as a drug to avoid in older adults due to anticholinergic adverse effects including urinary retention, cognitive impairment, constipation, and blurred vision. The anticholinergic burden score (ACB scale) assigns diphenhydramine a score of 3, the maximum, indicating definite anticholinergic activity. Resmetirom itself carries no anticholinergic activity, so this is a unidirectional pharmacodynamic concern from the diphenhydramine side.

The clinical problem is that MASH patients are frequently older adults who may already be taking other anticholinergic medications (bladder antimuscarinics, tricyclic antidepressants, or antipsychotics). Adding diphenhydramine can push total anticholinergic burden above a threshold associated with acute cognitive dysfunction. A JAMA Internal Medicine study (N=3,434 adults, mean follow-up 7.3 years) found that cumulative anticholinergic exposure was associated with a hazard ratio of 1.54 for dementia. While that study tracked long-term use, shorter-term cognitive effects remain relevant for medication adherence and safety monitoring in MASH patients on resmetirom.

Severity Classification and Clinical Risk Stratification

Standard drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) generally classify the resmetirom, diphenhydramine interaction as moderate, driven by the pharmacodynamic overlap rather than a pharmacokinetic catastrophe. The following three-tier framework helps clinicians triage individual patients.

Tier 1: Lower Risk

Patient profile: younger than 60, no additional CNS-active medications, Child-Pugh A liver disease, using diphenhydramine once or twice per week at 25 mg. Recommendation: counsel on residual morning sedation, advise against driving within 8 hours of dose, and document the conversation.

Tier 2: Intermediate Risk

Patient profile: age 60 to 74, one additional sedating medication (e.g., a low-dose SSRI with mild sedation), Child-Pugh A with fibrosis score approaching F3, using diphenhydramine three or more nights per week at 50 mg. Recommendation: avoid routine diphenhydramine use. Offer doxylamine as an equally OTC-available but shorter-acting alternative, or refer for cognitive behavioral therapy for insomnia (CBT-I), which a meta-analysis in Annals of Internal Medicine found superior to pharmacotherapy at 6-month follow-up. Reassess liver function panel monthly for the first 3 months.

Tier 3: Higher Risk

Patient profile: age 75 or older, two or more CNS-active or anticholinergic medications, approaching Child-Pugh B status, using diphenhydramine nightly at 50 mg. The 2023 Beers Criteria and the American Geriatrics Society guidance explicitly contraindicate diphenhydramine in this group regardless of resmetirom use. Discontinue diphenhydramine. Address sleep disorder through CBT-I, melatonin 0.5 to 3 mg (low anticholinergic burden), or specialist referral.

Monitoring Parameters

Liver Function Tests

Resmetirom is associated with elevations in ALT and AST in a minority of patients. The MAESTRO-NASH trial reported transaminase elevations above three times the upper limit of normal in 3.1% of the 80 mg arm and 4.4% of the 100 mg arm versus 1.4% placebo. Diphenhydramine at high cumulative doses adds hepatic metabolic demand. Baseline liver function tests before initiating resmetirom are mandated by the label, and the HealthRX clinical team recommends repeating them at 4 and 12 weeks if diphenhydramine is used concurrently, even intermittently. The FDA label specifies ALT/AST monitoring at 3 months and periodically thereafter.

Cognitive Function Screening

For patients in Tier 2 or Tier 3, a brief cognitive screen (e.g., the Montreal Cognitive Assessment, MoCA) at baseline and at 3 months provides a documented safety net. Diphenhydramine-related cognitive impairment is reversible on discontinuation in most cases, but early identification prevents falls, medication errors, and missed resmetirom doses.

Sedation Diary

A simple patient-reported sedation diary, asking the patient to rate morning alertness on a 0 to 10 scale daily for the first 2 weeks of concurrent use, costs nothing and catches accumulation effects quickly. Scores below 6 on 3 consecutive mornings should trigger a phone or telehealth visit to review the medication list.

Dose Adjustment Guidance

The FDA label for resmetirom does not require a dose adjustment specifically for diphenhydramine co-administration. Resmetirom is dosed at 80 mg once daily for patients weighing less than 100 kg and 100 mg once daily for those weighing 100 kg or more, per the approved prescribing information. No modification of that weight-based dosing is needed based on diphenhydramine use alone.

For diphenhydramine, dose reduction is always appropriate when hepatic impairment is present. Starting at 12.5 mg rather than the standard 25 to 50 mg OTC dose, and limiting use to no more than two nights per week, reduces both peak exposure and anticholinergic accumulation. Patients should be told explicitly that "more is not better" with OTC sleep aids and that the standard package labeling was developed in healthy adults without liver disease. FDA OTC monograph data on nighttime sleep aids includes dosing recommendations that do not account for hepatic impairment, making prescriber guidance essential.

Patient Counseling Points

Prescribers and pharmacists should address six specific counseling points with every MASH patient starting resmetirom.

First, ask directly about OTC sleep aids, allergy medications, and cold-and-flu products, because diphenhydramine is an ingredient in more than 40 branded OTC products including Benadryl, ZzzQuil, Unisom SleepTabs, Tylenol PM, and Nyquil. A review in the American Journal of Health-System Pharmacy found that patients underreport OTC antihistamine use by roughly 50% when not asked specifically.

Second, explain that having liver disease changes how long diphenhydramine stays active in the body. A dose that cleared overnight in their twenties may linger well into the next afternoon now.

Third, warn about driving and operating heavy machinery for at least 8 hours after any diphenhydramine dose while on resmetirom. Residual sedation is the most common real-world harm.

Fourth, instruct patients to skip diphenhydramine entirely on nights before morning labs or clinic visits to avoid confounding sedation scores and cognitive screens.

Fifth, recommend practical non-pharmacological alternatives: sleep hygiene adjustments, light-blocking curtains, fixed wake time, and restriction of caffeine after noon. These approaches are effective and carry zero drug interaction risk.

Sixth, document the discussion in the patient's chart and set a reminder for a 4-week follow-up call specifically asking about sleep quality and daytime alertness.

Special Populations

Older Adults

Adults aged 65 and older represent a disproportionate share of both MASH diagnoses and OTC diphenhydramine purchases. The MAESTRO-NASH trial enrolled patients with a mean age of 54 years, meaning limited trial-based safety data exist for the 65-plus segment. The 2023 Beers Criteria state: "Avoid diphenhydramine in older adults because of its highly anticholinergic properties; increased risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity." That recommendation applies regardless of what other drugs the patient is taking, making resmetirom co-administration a secondary concern that still reinforces the primary recommendation to avoid.

Patients With Obesity

Resmetirom's approved indication includes patients with obesity and MASH. Adipose tissue can sequester lipophilic drugs like diphenhydramine, extending its volume of distribution and prolonging effect duration. A pharmacokinetics study in obese adults found that volume of distribution for lipophilic antihistamines increased by 30 to 50% compared with normal-weight controls, with corresponding increases in terminal half-life. For a MASH patient who is also obese, the same 25 mg diphenhydramine tablet carries a longer and less predictable pharmacological effect.

Patients on Concomitant Statins

MASH patients are frequently on statins. Resmetirom lowered LDL cholesterol by approximately 16% in MAESTRO-NASH (a secondary endpoint), which means some clinicians may adjust statin doses. Several statins are P-gp substrates (e.g., rosuvastatin). Adding diphenhydramine on top of resmetirom's P-gp inhibition does not materially change the statin picture, but the prescriber should track the full medication list for cumulative P-gp substrate burden. The FDA's transporter interaction guidance provides current classification tables for clinical decision-making.

Alternatives to Diphenhydramine for Sleep in MASH Patients

Several options carry a lower interaction burden than diphenhydramine in a resmetirom-treated patient.

Melatonin 0.5 to 3 mg: No significant CYP2C8 interaction. Minimal CNS depression at physiologic doses. A meta-analysis in PLOS ONE (13 RCTs, N=1,683) found melatonin reduced sleep onset latency by 7.06 minutes versus placebo. Modest but meaningful with a clean safety profile.

CBT-I: The American Academy of Sleep Medicine designates CBT-I as first-line treatment for chronic insomnia. An Annals of Internal Medicine meta-analysis (N=2,189 across 20 RCTs) found CBT-I produced remission in 40 to 60% of patients at 6 months, outperforming pharmacotherapy on sustained outcomes. No drug interaction risk whatsoever.

Low-dose doxepin 3 to 6 mg: FDA-approved for insomnia, selective H1 antagonism at these doses, and lower anticholinergic burden than diphenhydramine at standard doses. Hepatic metabolism via CYP2C19 and CYP2D6 requires dose caution in advanced liver disease but is a viable alternative for many MASH patients. The FDA label for Silenor (doxepin 3 mg, 6 mg) specifies use in adults with sleep maintenance insomnia.

Suvorexant (Belsomra) 10 to 20 mg: Orexin receptor antagonist with a different mechanism. A moderate CYP3A4 substrate, not a CYP2C8 issue, so pharmacokinetic overlap with resmetirom is minimal. The FDA label for Belsomra advises dose reduction if co-administered with moderate CYP3A4 inhibitors, and resmetirom is not classified as such.